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Abstract
Autophagy is a host defensive mechanism responsible for eliminating harmful cellular components 
through lysosomal degradation. Autophagy has been known to either promote or suppress various 
cancers including colorectal cancer (CRC). KRAS mutation serves as an important predictive marker for 
epidermal growth factor receptor (EGFR)-targeted therapies in CRC. However, the relationship between 
autophagy and KRAS mutation in CRC is not well-studied. In this single-centre study, 92 formalin-fixed 
paraffin-embedded (FFPE) tissues of CRC patients (42 Malaysian Chinese and 50 Indonesian) were 
collected and KRAS mutational status was determined by quantitative PCR (qPCR) (n=92) while the 
expression of autophagy effector (p62, LC3A and LC3B) was examined by immunohistochemistry 
(IHC) (n=48). The outcomes of each were then associated with the clinicopathological variables (n=48). 
Our findings demonstrated that the female CRC patients have a higher tendency in developing KRAS 
mutation in the Malaysian Chinese population (p<0.05). Expression of autophagy effector LC3A was 
highly associated with the tumour grade in CRC (p<0.001) but not with other clinicopathological 
parameters. Lastly, the survival analysis did not yield a statistically significant outcome. Overall, this 
small cohort study concluded that KRAS mutation and autophagy effectors are not good prognostic 
markers for CRC patients.  
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INTRODUCTION
Colorectal cancer (CRC) resulted in 9.2% of 
cancer-related death worldwide which is ranked 
second after lung cancer (18.4%) according to 
Global Cancer Observatory 2018, World Health 
Organization (WHO).1 There were approximately 
1.85 million new cases in 2018 which was 
ranked third after lung and breast cancers. In 
Malaysia, CRC is the second most common 
cancers and ranked third in terms of mortality 
rate.1 A recent key review suggested that lifestyle 
modification, nutritional factors, screening and 
chemoprevention are crucial in controlling 
the CRC incidence and mortality rates.2 Other 
emerging challenges are standardisation of 
molecular biomarker testing and guidance on 
personalised therapies in CRC which require 
global concerted efforts.3,4
 The aetiology of CRC is complex and both 
genetic and environmental factor have huge 
impacts on it. One of the important pathways 
is EGFR (epidermal growth factor receptor) 
signalling pathway which involves KRAS 
(Kirsten rat sarcoma viral oncogene), NRAS 
(neuroblastoma ras viral oncogene homolog) 
and BRAF (v-raf murine sarcoma viral oncogene 
homolog B1) genes.4,5 In the past decade, 
this pathway has shown to play pivotal role 
in CRC development and progression, and 
subsequently serve as a therapeutic target for 
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cancer therapies especially in advanced stage 
or metastatic CRC (mCRC).6 KRAS mutation 
occur in approximately 30-40% CRC and it 
results in tumour aggressiveness and confers 
poorer survival in CRC patients.7 It also acts as 
an excellent predictive marker for the resistance 
of EGFR-targeted therapies.7 
 Since the cause of CRC is multifactorial, 
many other oncogenic proteins from other 
biological pathways have also been studied 
on their linkage with CRC and their potential 
use as biomarkers. For example, colon cancer 
secreted protein-2 (CCSP-2) was shown to be 
a promising marker for detection of metastatic 
or recurrent CRC8 while activated EGFR and 
HER3 proteins could act as predictive markers 
for better overall survival in patients treated by 
anti-EGFR therapy.9 Recently, autophagy which 
is a self-defensive mechanism that degrades 
and eradicates damaged cellular proteins or 
organelles, has shown to play a double-faced 
role in either promoting or suppressing the 
tumour growth in CRC.10 This starvation-induced 
mechanism has also been extensively studied 
for its potential as prognostic and/or predictive 
biomarkers in CRC.11 
 Interestingly, an in vitro study showed that 
the expression of mutated KRAS upregulated the 
autophagy followed by the activation of MEK/
ERK pathway in CRC, and resulted in cancer 
cell survival during starvation.12 Furthermore, 
immunohistochemical analysis of CRC tissues by 
Schmitz et al. revealed that autophagy effectors 
including LC3, p62 and Beclin-1 could serve as 
promising prognostic markers.13 However, these 
findings have not been further investigated and 
there is certainly a big gap of understanding 
between KRAS mutation and autophagy in 
CRC. This study aimed to evaluate the KRAS 
mutation status and autophagy expression of 
CRC tissues collected from a single centre. The 
findings were then correlated with the patients’ 
clinicopathological parameters and their potential 
use as prognostic marker were investigated. 
MATERIALS AND METHODS
Reagents
Antibodies were purchased from Abcam 
(Cambridge, UK) and Cell Signalling Technology 
(Danvers, MA, USA) for this study (Table 1). 
Beta-actin antibody was used as the assay control 
for IHC staining. All chemicals and solvents were 
purchased from Merck (Darmstadt, Germany). 
Tissue sample and clinicopathological data 
collection
Archived formalin-fixed paraffin-embedded 
(FFPE) tissue blocks from 92 patients (42 
Malaysian Chinese and 50 Indonesian) diagnosed 
and underwent colectomy at the Mahkota 
Medical Centre from the year 2013 to 2015 were 
retrieved for KRAS mutation study. Out of the 
92 cases, tumour and adjacent normal mucosa 
blocks from 48 patients with complete clinical 
pathological data were chosen for autophagy 
staining. This study has been approved by 
Sunway University Research Ethics Committee 
(SUNREC 2017/051), Sunway Medical Centre 
Independent Research Ethics Committee 
(013/2017/ER), and National Medical Research 
Ethic Committee (NMRR-18-1137-42073).
Haematoxylin and Eosin (H&E) staining
The tissue blocks were sectioned at a thickness 
of 4 μm and placed on a silane-coated slides 
(MUTO #5116, Tokyo, Japan) before heating 
at 60˚C for 1 h. The paraffin was then removed 
using the decloaking chamber (Biocare Medical 
NxGen, Pacheco, CA, USA) and DepART 
solution (Biocare Medical #BRI4044G1, 
Pacheco, CA, USA) at 60˚C for 20 min. After 
the slides were washed, the sections were stained 
with haematoxylin (Leica #3801575, Wetzlar, 
Germany) for 8 min followed by washing for 
5 min under running tap water. The tissues 
were then differentiated in 1 % acid alcohol 
(concentrated HCL in 70 % ethanol) for 30 
sec and washed in running tap water for 1 
min. Then, the slides were immersed in 0.1 M 
TABLE 1: Details of antibodies used for autophagy examination in tissues





p62/ SQSTM1 Monoclonal Rabbit 1:500 EPR18351 Abcam 
LC3A Monoclonal Rabbit 1:1,000 D50G8 Cell Signalling Technology 
LC3B Monoclonal Rabbit 1:1,000 D11 Cell Signalling Technology  
Beta-actin Monoclonal Mouse 1:3,000 8H10D10 Cell Signalling Technology 
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sodium bicarbonate for 1 min to allow bluing 
followed by washing in running tap water for 
5 min. The water was removed by dipping the 
slides in 95 % ethanol for 10 X. The tissues 
were counterstained by immersing the slides in 
eosin (Leica #3801600, Wetzlar, Germany) for 
2 min followed by dehydration in 95 % ethanol 
for 5 min. Further dehydration of the tissues was 
performed through immersion of the slides in 2 
changes of absolute ethanol for 5 min each. The 
tissues were then cleared in 2 changes of xylene 
for 5 min each before mounted by xylene-based 
mounting medium (Leica #3801732, Wetzlar, 
Germany). The slides were then verified and 
the tumour portion of each slide was marked 
by senior pathologists. 
Immunohistochemistry (IHC)
Sections were prepared as described above. 
The paraffin removal and antigen retrieval were 
performed using the FLEX Target Retrieval 
Solution Low pH (Agilent Dako #K800521, 
Santa Clara, CA, USA) for LC3A and LC3B and 
High pH (Agilent Dako #K800521, Santa Clara, 
CA, USA) for p62/SQSTM1 staining. The slides 
were heated in the decloaking chamber at 110˚C 
for 30 min and washed in deionised water to 
remove the retrieval solution residue. The tissues 
were stained using the REAL Envision Detection 
System (Agilent Dako #K500711, Santa Clara, 
CA, USA) according to the manufacturer’s 
instructions. The tissues were blocked by using 
the Endogenous Enzyme Block (Agilent Dako 
#S202386, Santa Clara, CA, USA) for 10 min. 
The tissues were then incubated overnight in the 
antibody solution according to the respective 
dilutions (Table 1) in the humidified slides 
chamber at 4 ̊ C. The tissues were then incubated 
with the HRP-Polymer (Agilent Dako #5007, 
Santa Clara, CA, USA) for 30 min and the DAB+ 
chromogen (Agilent Dako #5007, Santa Clara, 
CA, USA) was applied for 5 min. The tissues 
were then counterstained with haematoxylin and 
dehydrated with ethanol and cleared with xylene 
before mounting. The IHC slides were then 
assessed by the senior pathologists for scoring. 
Each slide was scored for percentage of positivity 
and intensity of stained cells as follows: 0% (0), 
<10 % (1), 10-25 % (2), 26-50 % (3), 51-75 % 
(4), >75 % (5); negative (0), weak (1), mild (2), 
moderate (3), strong (4). The sum of positivity 
and intensity was used as a total staining score 
for each protein. Score of 0 was represented 
as ‘negative’ staining, while 1 to 5 and 6 to 9 
were represented as ‘low’ and ‘high’ staining, 
respectively. Similar IHC protocol was used 
for all the antibodies following the optimised 
dilutions (Table 1).  
KRAS mutation analysis
A total of 5 sections from each FFPE tissue at 
a thickness of 10 μm was collected for DNA 
extraction. Paraffin was dissolved by xylene and 
the DNA was extracted using QIAamp DNA 
FFPE Tissue Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. 
The quality of DNA was examined by checking 
the A260/A280 ratio using SpectraMax QuickDrop 
micro volume spectrophotometer (Molecular 
Devices, San Jose, CA, USA). Generally, the 
DNA was diluted at a ratio of 1:10 for the KRAS 
mutation testing using Therascreen KRAS RGQ 
PCR Kit (Qiagen. Hilden, Germany) according 
to the manufacturer’s protocol. This detection 
was performed on Rotor-Gene Q MDx 5plex 
HRM (Qiagen, Hilden, Germany) and analysed 
using Rotor-Gene Q Software, version 2.3.1.49 
(Qiagen, Hilden, Germany).
Association and statistical analysis
The primary outcome was overall survival, which 
was defined as the time from the initiation of 
surgery to death due to the disease or to the date 
of the last follow-up. Significant differences 
in the clinical-pathological variables between 
each group were tested using the Fisher’s exact 
or Chi-square tests. The distribution of overall 
survival was estimated using the Kaplan-Meier 
analysis and log-rank test. The analyses were 
performed using the Statistical Package for Social 
Sciences, version 26.0 (SPSS Inc, Chicago, IL, 




This study cohort consists of 42 Malaysian 
Chinese and 50 Indonesian with unknown 
ethnicity, respectively. In combination, CRC 
was more prevalent in females (Table 2), CRC 
patients of Indonesian population had lower 
mean age (54.8-58.9) than the Malaysian 
Chinese population (62.7-65.7) In terms of 
the tumour characteristics, higher incidence 
was seen in advanced stage (stage III and IV), 
moderate tumour grade, tumour size less than 
5cm, and in left colon than in rectum. Proximal 
colon (caecum, ascending, hepatic flexure and 
transverse colon) was termed as right colon 
while distal colon (splenic flexure, descending, 
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sigmoid and rectosigmoid colon) was termed as 
left colon. Higher frequencies were also found 
in T3 or T4 stage, histopathology with positive 
lymph nodes, and localised tumours without 
infiltrating lymphocytes (Table 2). 
KRAS mutation and its prognostic value
DNA was extracted from the tissues and KRAS 
gene mutation was determined by PCR method. 
From the 92 patients, 44% had KRAS mutation, 
12ASP (20%) being the most frequent mutation 
in codon 12 followed by 13ASP (14%) in 
codon 13 (FIG 1A). When assessed separately, 
Indonesian (50%) has a higher KRAS mutation 
rate than Malaysian Chinese (36.6%) (FIG 1B). 
Furthermore, the mutation was more frequent 
in the right side of colon (54.5%) compared 
to left colon (38.5%) and rectum (43.3%) 

























Female 12 13 25 0.01* 14 11 25 0.572
Male 15 2 17 11 14 25











Poor 2 0 2 0.551 1 3 4 0.304
Moderate 23 14 37 23 19 42
Unknown 2 1 3 1 3 4
Tumour size
<5cm 17 9 26 0.141 16 14 30 0.837
>5cm 10 4 14 8 10 18
Unknown 0 2 2 1 1 2
Tumour site
Colon 13 8 21 0.966 12 13 25 0.999
Rectum 14 6 20 13 12 25
Unknown 0 1 1 0 0 0
Staging
I and II 9 3 12 0.485 5 6 11 0.999
III and IV 18 12 30 20 19 39
Tumour stage
T1 and T2 1 1 2 0.999 2 0 2 0.490
T3 and T4 26 14 40 23 25 48
Lymph node metastases
N- 10 3 13 0.314 5 6 11 0.999
N+ 17 12 29 20 19 39
Distant metastasis
M- 25 15 40 0.530 23 19 42 0.247
M+ 2 0 2 2 6 8
Tumour infiltrating lymphocytes
Present 8 4 12 0.999 11 9 20 0.773
Absent 19 11 30 14 16 30
SD – standard deviation; N-/ N+ - Histopathology with negative or positive nodes; M-/ M+ - Not metastatic 
or metastatic; * - Statistically significant
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FIG. 1: KRAS mutation study of 92 colorectal cancer 
patients. (A) Frequency of KRAS mutation in: 
(A) codon 12 and 13; (B) Malaysian Chinese 
and Indonesian; and (C) tumour site in left 
or right colon or rectum
FIG. 2: Survival analysis of colorectal cancer patients 
with KRAS mutation.
(FIG 1C) in both populations combined. To 
assess the correlation of KRAS mutation with 
clinicopathological variables, Fisher’s exact 
or Chi-square tests were performed. In the 
Malaysian Chinese population, KRAS mutation 
significantly correlated with the gender 
(p<0.05), but did not show any correlation 
with other clinicopathological variables 
(Table 2). Kaplan-Meier curves showed that the 
CRC patients with KRAS mutation exhibited 
poorer survival compared to the wild-type 
(FIG 2). However, the difference was not 
signifi cant from the statistical analysis. This 
suggests that KRAS mutation does not have any 
prognostic value for the CRC patients. 
Autophagy expression in colorectal cancer tissues 
and its prognostic value
FIG 3 demonstrates cytoplasmic and perinuclear 
expression of LC3A, LC3B, and p62 in malignant 
glands of colorectal adenocarcinoma from 48 
patients. Different levels of expression (negative, 
low or high) was determined based on the IHC 
scores by the pathologists. Negative staining of 
p62 was not shown as all tissues showed positive 
staining. The scoring was then summarised 
and tabulated in Table 3. Overall, all tissues 
expressed p62 and 93.8 % had high expression 
while only 14.6 % and 25 % of LC3A and LC3B 
expression were seen, respectively. Tissues which 
simultaneously express the autophagy markers 
were shown in FIG 4. 64.6% of p62-positive 
tissues expressed p62 only while 4.2% expressed 
LC3A, LC3B and p62. 10.4% co-expressed 
LC3A and p62 while 20.8% co-expressed LC3B 
and p62. Correlation study showed that LC3A 
expression was signifi cantly correlated with the 
tumour grading (p < 0.05), but not with other 
clinical pathological variables (Table 3).
 As all CRC tissues expressed p62, we 
examined whether this expression was cancer-
specifi c using the adjacent non-cancer tissues 
from the 48 patients. Only 44 sets of non-tumour 
tissues were included in this study as the rest of 
blocks failed to be retrieved. Our fi ndings showed 
that 94.5 % of the non-cancer tissues had p62 
staining (86.4 % showing high and 9.1 % showing 
low expression) (Table 4). The p62 expression in 
tumour tissues was associated with the adjacent 
non-cancer tissues (p < 0.05). On the other hand, 
LC3A and LC3B (only one case showed low 
expression) were not or mildly expressed in the 
adjacent non-tumour tissues (Table 4). Further, 
Kaplan-Meier survival analysis was performed 
and the outcome showed that the three autophagy 
proteins were not suitable to be used as prognostic 
markers (FIG 5). 
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FIG. 3: Different expression of LC3A, LC3B and p62 in colorectal cancer tissues. Negative staining of p62 is 
not shown as all tissues express p62. Images were captured at x400 magnification.
FIG. 4: Simultaneous expression of p62, LC3A and/or LC3B in colorectal cancer tissues.
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Female 1 28 0.554 25 1 3 0.527 23 4 2 0.198
Male 2 17 16 2 1 13 6 0
Age
<59 1 20 0.999 18 2 1 0.546 16 5 0 0.423
>59 2 25 27 1 3 20 5 2
Tumour grading
Poor 1 4 0.375 1 3 1 0.0001* 3 1 1 0.305
Moderate 2 37 36 0 3 29 9 1
Unknown 0 4 4 0 0 4 0 0
Tumour size
<5cm 1 28 0.437 27 2 0 0.061 20 8 1 0.628
>5cm 2 14 11 1 4 13 2 1
Unknown 0 3 3 0 0 2 0 0
Tumour site
Colon 2 29 0.966 26 2 3 0.987 23 6 2 0.817
Rectum 1 15 14 1 1 12 4 0
Unknown 0 1 1 0 0 1 0 0
Staging
I and II 1 8 0.472 8 0 1 0.667 8 1 0 0.536
III and IV 2 37 33 3 3 28 9 2
Tumour stage
T1 and T2 0 2 0.999 2 0 1 0.837 1 1 0 0.573
T3 and T4 3 43 39 3 3 35 9 2
Lymph node metastases
N- 1 9 0.512 8 0 2 0.235 9 1 0 0.446
N+ 2 36 33 3 2 27 9 2
Distant metastasis
M- 3 40 0.999 36 3 4 0.621 31 10 2 0.394
M+ 0 5 5 0 0 5 0 0
Tumour infiltrating lymphocytes
Present 1 32 0.227 27 3 3 0.45 24 7 2 0.61




1 23 0.999 20 2 2 0.836 17 5 2 0.384
KRAS 
mutated
2 22 21 1 2 19 5 0
Neg. – Negative; N-/ N+ - Histopathology with negative or positive nodes; M-/ M+ - Not metastatic or metastatic; 
* - Statistically significant
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DISCUSSION
KRAS mutation is one of the frequent RAS gene 
mutations in solid tumours such as pancreas, 
lung and CRC. Mutated KRAS mainly drives 
malignant transformation in cancers while 
acting as an important biomarker of resistance 
FIG. 5: Survival analysis of colorectal cancer patients with (A) LC3A; (B) LC3B; and (C) p62 expression.
to anti-EGFR therapy which is a targeted therapy 
for mCRC.4,5 Our studied CRC cohort showed 
44% of KRAS mutation which is consistent 
to the consensus global rate of 30 to 50%.14,15 
Interestingly, the Indonesian patient cohort alone 











Tissue type p value









LC3A Negative 41 85.4 44 100 NA
Low 3 6.3 0 0
High 4 8.3 0 0
LC3B Negative 36 75 43 97.7 0.137
Low 10 20.8 1 2.3
High 2 4.2 0 0
p62 Negative 0 0 2 4.5 0.002*
Low 3 6.3 4 9.1
High 45 93.7 38 86.4
NA – not applicable; * – Statistically significant
could be due to the small sample size. Among 
the mutations, 12ASP was the most common 
mutation which is consistent to the findings from 
RASCAL (Kirsten RAS in-Colorectal-Cancer 
Collaborative Group) and RASCAL II studies.14,15 
From the association studies, our findings 
showed that KRAS mutation was significantly 
associated with female gender in Malaysian 
Chinese only, but not in Indonesian cohort 
and other clinicopathological characteristics. 
This finding is consistent with another study 
with larger sample size involving 226 CRC 
Chinese patients in China.16 However, there 
was a study involving 1,735 patients in France 
showed higher frequency of KRAS mutation in 
males.17 Consistent to a previous study,18 KRAS 
mutation was not associated with the prognosis 
in CRC patients. Several studies demonstrated 
that specific mutations in codon 12 might have 
prognostic values.19,20 However, this question 
can not be addressed in this study due to the 
limitation of small sample size. It would also 
be valuable to determine other mutations such 
as NRAS, BRAF and PIK3CA and important 
features such as microsatellite instability 
(MSI) status in association with KRAS when 
assessing its prognostic implication as described 
elsewhere.21,22
 To our best knowledge, this is the only study 
with Malaysian and Indonesian cohort focusing 
on the clinicopathological and prognostic 
implications of autophagy proteins in CRC. 
Out of the three proteins, LC3A was found to 
be associated with the tumour grade of CRC. 
This is in line with a previous study showing the 
association of another LC3 isoform, LC3B with 
the tumour grade.23 LC3 protein is expressed as 
three splice variants- LC3A, LC3B and LC3C 
with unique tissue distribution.24 LC3A was 
not expressed in adjacent normal tissues, so as 
LC3B in which only 1 of 44 non-cancer tissues 
showed weak-positive expression (Table 4). 
This finding is contradictory to a study which 
demonstrated that LC3B was expressed both 
in cancer cells and normal epithelial cells.23 
Specifically, the same study showed that the 
LC3B-II expression was significantly higher in 
cancer tissue than in normal tissue. The LC3 is 
proteolytically cleaved by a protease to form 
LC3-I which is then conjugated with ATGs 
to a phosphatidylethanolamine (PE) moiety to 
generate LC3-II.10 LC3-II is inserted into the 
membrane of autophagosomes and undergoes 
degradation upon autolysosome fusion.10 
Through Western blot assay, the LC3-I/LC3-
II ratios are usually determined to corelate to 
the number of autophagosomes.25 It would be 
interesting to study the subtype of LC3 protein 
and its association with the clinical pathological 
features in future investigations. 
 Another autophagy protein p62, on the 
other hand is a substrate for LC3 to facilitate 
degradation during autophagy.10 In this study, 
expression of p62 was correlated in both 
tumour and non-tumour tissues. In contrast, 
it has been described elsewhere that the p62 
level was higher in the tumour tissues than 
those in normal tissues.26,27 On top of that, we 
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found that there were intense p62 staining in 
the nerve plexus cells both in the tumour and 
non-tumour tissues (data not shown). This has 
been previously reported in the colon tissues 
but in another autophagy marker, LC3.23,28 In 
the survival analysis, autophagy proteins did not 
show any prognostic value in CRC patients which 
is contrasting numerous large-scale studies.26,29 
This might be due to the variation of sample size 
or the ethnicities of studied cohort which deserve 
future studies. In this study, we conclude that 
autophagy effectors LC3A, LC3B and p62 are 
not associated with the patient clinicopathologic 
features (except for LC3A and tumour grading) 
and cannot be used as prognostic markers. Further 
investigations are warranted to validate these 
findings with a larger scale of CRC cohorts. 
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